AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
TransMedics Q2 Earnings Estimates Set to Disappoint
ByAinvest
Monday, Jul 14, 2025 12:29 am ET1min read
TransMedics has experienced a rollercoaster ride over the past year, with a 55% drop after Q3 2024 results that met management's expectations. However, the company's strong execution and trustworthiness have led to its recovery. Analyst estimates for Q2 are expected to be lower, but the company's solid performance suggests that it will continue to recover.
TransMedics Group (TMDX) has experienced a tumultuous journey over the past year, with a significant drop of 55% following Q3 2024 results that met management's expectations. However, the company's strong execution and trustworthiness have led to a recovery. Analyst estimates for Q2 are expected to be lower, but the company's solid performance suggests a continued recovery.Analysts' ratings for TMDX have been mixed. Out of nine analysts, five have a "Buy" rating, four have a "Hold" rating, and zero have a "Sell" rating, reflecting a moderate buy consensus [1]. The top analysts, including TD Cowen, William Blair, and Piper Sandler, have reiterated their buy ratings, citing strong financial outlooks and robust revenue growth [1].
The average 12-month price target for TMDX is $135.29, with a high forecast of $170.00 and a low forecast of $103.00. This represents an average 20.30% upside from the last price of $112.46 [1]. Analysts at TD Cowen and Piper Sandler have the highest price targets at $170.00 and $145.00, respectively, while J.P. Morgan and Robert W. Baird have the lowest targets at $103.00 and $120.00, respectively [1].
TMDX's earnings forecast for the next quarter is $0.45, with a range of $0.34 to $0.59. The company has a strong track record of beating its earnings estimates, doing so 75.00% of the time in the past 12 months [1]. Sales forecasts for the next quarter are $146.74M, with a range of $144.00M to $150.00M, reflecting a 75.00% beat rate over the past year [1].
Despite the mixed analyst ratings, TMDX's financial performance and earnings beat rates suggest a company that is on the path to recovery. Investors should closely monitor the company's earnings reports and analyst updates to make informed decisions.
References:
[1] https://www.tipranks.com/stocks/tmdx/forecast
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet